Tussen hype en hoop
Systeemtherapie September 1, 2025 DOI: 10.5553/st/092436312025037003004 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Interventions | Psilocybin Ketamine MDMA |
| Key points | Argues that psychedelics such as psilocybin, ketamine, and MDMA can be integrated into systemic psychotherapy, potentially helping to break rigid thinking patterns, strengthen connections, and increase resilience, while emphasizing "set and setting" and acknowledging ethical and practical concerns such as legislation, training, and contraindications. |
Abstract
Psychotherapy with the use of psychedelics is an emerging field that evokes both curiosity and scepticism. This article explores how these substances, despite their controversial reputation, can have their therapeutic value within a systemic context. For centuries, psychedelics have been used for spiritual and healing purposes and received considerable scientific attention in psychiatry in the 1940s and 1950s. After a lengthy period of prohibition and societal resistance, there has recently been a resurgence of research into their therapeutic uses. Drugs such as psilocybin, ketamine and MDMA appear promising in treating human mental suffering. In addition, they act on how we relate with the world around us, our near ones, ourselves. The article describes how psychedelics can be integrated into systemic therapy and emphasizes the importance of “set and setting” for a safe and effective experience. Psychedelic-assisted psychotherapy can help break rigid thinking patterns, strengthen connections, and increase resilience. Although results are promising, there are ethical and practical issues, such as legislation, training and counterindications. Besides additional research, an open conversation within our profession is necessary.